ArticleNeuropsychiatric disease and treatment2025
Diagnostic Value of Carotid Intima-Media Thickness Combined with Periventricular White Matter Hyperintensities for Mild Cognitive Impairment in Parkinson's Disease.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine the independent association of carotid intima-media thickness (CIMT) and periventricular white matter hyperintensities (PWMHs) with mild cognitive impairment in Parkinson's disease (PD-MCI) and evaluate the diagnostic value of CIMT combined with PWMHs for PD-MCI. Patients and Methods: A prospective cohort of 541 PD patients was enrolled, and all patients underwent carotid artery ultrasound for mean CIMT measurement and 3T brain MRI for PWMH volume quantification. PD-MCI was diagnosed via comprehensive neuropsychological assessment (10 tests across 5 domains) based on established criteria, ie, at least two tests demonstrated abnormal results, either one impaired test in two different cognitive domains or two impaired tests in a single cognitive domain. Multivariate analysis was conducted to determine the independent association, and the receiver operating characteristic (ROC) curve was employed to assess the diagnostic values, and the Results: PD-MCI prevalence was 45.5% (246/541). Multivariate analysis, adjusting for education duration, Cys C levels, disease duration, total brain WMHs, hypertension, hyperlipidemia, and age, identified PWMHs [odds ratio (OR): 2.114, 95% confidence interval (CI): 1.391-4.586], CIMT (OR: 2.027, 95% CI: 1.485-4.281), homocysteine (OR: 1.551, 95% CI: 1.172-2.680), Hoehn and Yahr stage (OR: 2.243, 95% CI: 1.534-4.736), and MDS-UPDRS part III score (OR: 1.416, 95% CI: 1.158-2.465) as independent PD-MCI predictors. ROC analysis demonstrated significantly higher diagnostic value for the combination of CIMT and PWMHs (AUC: 0.908, 95% CI: 0.882-0.934) compared to either marker alone (AUC: 0.705, 95% CI: 0.661-0.750 for PWMHs; AUC: 0.722, 95% CI: 0.678-0.765 for CIMT; both Conclusion: The combination of CIMT and PWMHs provides significantly superior diagnostic value for PD-MCI compared to either marker individually, and this integrated model suggests a potential tool for identifying PD patients at high risk for cognitive decline.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.